235 related articles for article (PubMed ID: 15841634)
21. Imiquimod 5% cream following curettage without electrodesiccation for basal cell carcinoma: preliminary report.
Rigel DS; Torres AM; Ely H
J Drugs Dermatol; 2008 Jan; 7(1 Suppl 1):s15-6. PubMed ID: 18277458
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens.
Shumack S; Robinson J; Kossard S; Golitz L; Greenway H; Schroeter A; Andres K; Amies M; Owens M
Arch Dermatol; 2002 Sep; 138(9):1165-71. PubMed ID: 12224977
[TBL] [Abstract][Full Text] [Related]
23. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial.
Bath-Hextall F; Ozolins M; Armstrong SJ; Colver GB; Perkins W; Miller PS; Williams HC;
Lancet Oncol; 2014 Jan; 15(1):96-105. PubMed ID: 24332516
[TBL] [Abstract][Full Text] [Related]
24. Topical imiquimod treatment of superficial and nodular basal cell carcinomas in patients affected by basal cell nevus syndrome: a preliminary report.
Micali G; De Pasquale R; Caltabiano R; Impallomeni R; Lacarrubba F
J Dermatolog Treat; 2002 Sep; 13(3):123-7. PubMed ID: 12227875
[TBL] [Abstract][Full Text] [Related]
25. Clearance of basal cell and superficial squamous cell carcinomas after imiquimod therapy.
Warshauer E; Warshauer BL
J Drugs Dermatol; 2008 May; 7(5):447-51. PubMed ID: 18505136
[TBL] [Abstract][Full Text] [Related]
26. A preliminary study of imiquimod treatment in variants of basal cell carcinoma.
McCutcheon B; White K; Kotwall C; Germolic D; Rebolloso Y; Hamann MS; Stiles A
Am Surg; 2005 Aug; 71(8):662-5. PubMed ID: 16217949
[TBL] [Abstract][Full Text] [Related]
27. Treatment of facial superficial basal cell carcinomas with imiquimod 5% cream.
Mirza B; De'Ambrosis B
Clin Exp Dermatol; 2003 Nov; 28 Suppl 1():16-8. PubMed ID: 14616806
[TBL] [Abstract][Full Text] [Related]
28. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage.
Neville JA; Williford PM; Jorizzo JL
J Drugs Dermatol; 2007 Sep; 6(9):910-4. PubMed ID: 17941362
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo.
Urosevic M; Maier T; Benninghoff B; Slade H; Burg G; Dummer R
Arch Dermatol; 2003 Oct; 139(10):1325-32. PubMed ID: 14568837
[TBL] [Abstract][Full Text] [Related]
30. Imiquimod: in superficial basal cell carcinoma.
Oldfield V; Keating GM; Perry CM
Am J Clin Dermatol; 2005; 6(3):195-200; discussion 201-2. PubMed ID: 15943496
[TBL] [Abstract][Full Text] [Related]
31. Surgery Versus 5% Imiquimod for Nodular and Superficial Basal Cell Carcinoma: 5-Year Results of the SINS Randomized Controlled Trial.
Williams HC; Bath-Hextall F; Ozolins M; Armstrong SJ; Colver GB; Perkins W; Miller PSJ;
J Invest Dermatol; 2017 Mar; 137(3):614-619. PubMed ID: 27932240
[TBL] [Abstract][Full Text] [Related]
32. Treatment of cutaneous tumors with topical 5% imiquimod cream.
Alessi SS; Sanches JA; Oliveira WR; Messina MC; Pimentel ER; Festa Neto C
Clinics (Sao Paulo); 2009; 64(10):961-6. PubMed ID: 19841702
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerability of imiquimod 5% cream to treat periocular basal cell carcinomas.
Garcia-Martin E; Idoipe M; Gil LM; Pueyo V; Alfaro J; Pablo LE; Zubiri ML; Fernandez J
J Ocul Pharmacol Ther; 2010 Aug; 26(4):373-9. PubMed ID: 20698800
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream.
Beutner KR; Geisse JK; Helman D; Fox TL; Ginkel A; Owens ML
J Am Acad Dermatol; 1999 Dec; 41(6):1002-7. PubMed ID: 10570388
[TBL] [Abstract][Full Text] [Related]
35. Imiquimod in basal cell carcinoma: how does it work?
Dummer R; Urosevic M; Kempf W; Hoek K; Hafner J; Burg G
Br J Dermatol; 2003 Nov; 149 Suppl 66():57-8. PubMed ID: 14616353
[TBL] [Abstract][Full Text] [Related]
36. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe.
Gollnick H; Barona CG; Frank RG; Ruzicka T; Megahed M; Tebbs V; Owens M; Stampone P
Eur J Dermatol; 2005; 15(5):374-81. PubMed ID: 16172048
[TBL] [Abstract][Full Text] [Related]
37. Imiquimod-responsive basal cell carcinomas and factor XIIIa-enriched dendrocytes.
Quatresooz P; Piérard GE
Clin Exp Dermatol; 2003 Nov; 28 Suppl 1():27-9. PubMed ID: 14616809
[TBL] [Abstract][Full Text] [Related]
38. Immunocryosurgery for non-superficial basal cell carcinoma: a pro-spective, open-label phase III study for tumours ≤ 2 cm in diameter.
Gaitanis G; Bassukas ID
Acta Derm Venereol; 2014 Jan; 94(1):38-44. PubMed ID: 23722308
[TBL] [Abstract][Full Text] [Related]
39. Superficial basal cell carcinoma treated with imiquimod 5% topical cream for a 4-week period: a case series.
Ruiz-Villaverde R; Sánchez-Cano D; Burkhardt-Pérez P
J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):828-31. PubMed ID: 19646136
[TBL] [Abstract][Full Text] [Related]
40. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial.
Marks R; Gebauer K; Shumack S; Amies M; Bryden J; Fox TL; Owens ML;
J Am Acad Dermatol; 2001 May; 44(5):807-13. PubMed ID: 11312429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
